Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders fell 6932.76% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 5482.52%. This contributed to the annual value of -$297.4 million for FY2024, which is 4218.87% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Net Income towards Common Stockholders is -$130.1 million, which was down 6932.76% from -$115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$22.9 million during Q1 2021, with a 5-year trough of -$130.1 million in Q3 2025.
  • For the 5-year period, Crinetics Pharmaceuticals' Net Income towards Common Stockholders averaged around -$60.8 million, with its median value being -$53.4 million (2023).
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Net Income towards Common Stockholders tumbled by 2023.15% in 2023 and then crashed by 6932.76% in 2025.
  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$30.8 million in 2021, then crashed by 48.18% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then plummeted by 43.69% to -$80.4 million in 2024, then crashed by 61.85% to -$130.1 million in 2025.
  • Its last three reported values are -$130.1 million in Q3 2025, -$115.7 million for Q2 2025, and -$96.6 million during Q1 2025.